Investigational drug · Phase 2
BMF-219
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
5
Any phase or sponsor naming "BMF-219"
First trial start
2022
Aug 17, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMF-219", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes Mellitus
- Type 1 Diabetes Mellitus
Approved drugs for the same conditions: Type 2 diabetes · Type 1 diabetes · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "BMF-219" as an intervention, largest first.
- Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)Pivotal-lookingCompleted
Biomea Fusion Inc.Industry
NCT05731544 · 443 participants · Start Aug 17, 2022 · Primary completion Nov 18, 2024
Drug: BMF-219; Placebo · For: Type 2 Diabetes Mellitus
Sites: Canoga Park, California; Fountain Valley, California; La Mesa, California · 39 sites in all
Biomea Fusion Inc.Industry
NCT07254286 · 60 participants · Start Sep 11, 2025 · Primary completion Jan 14, 2026
Drug: Icovamenib; Icovamenib HPMC · For: Healthy Volunteer
Sites: Miami, Florida
Biomea Fusion Inc.Industry
NCT05153330 · 55 participants · Start Jan 24, 2022 · Primary completion Feb 13, 2025
Drug: BMF-219 · For: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Acute Mixed-Phenotype Leukemia and 12 more
Sites: Irvine, California; Los Angeles, California; Sacramento, California · 41 sites in all
Biomea Fusion Inc.Industry
NCT06152042 · 37 participants · Start Dec 28, 2023 · Primary completion May 20, 2025
Drug: BMF-219 · For: Type 1 Diabetes Mellitus
Sites: North Miami Beach, Florida; Morehead City, North Carolina; Norman, Oklahoma · 11 sites in all
Biomea Fusion Inc.Industry
NCT05631574 · 13 participants · Start Jan 12, 2023 · Primary completion Jan 15, 2025
Drug: BMF-219 · For: Non Small Cell Lung Cancer; Pancreatic Cancer; Colorectal Cancer and 14 more
Sites: Goodyear, Arizona; Encinitas, California; La Jolla, California · 23 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia.
Agarwal G, Tonk RK, Sangwan K · Leuk Lymphoma 2026
- Cascade-responsive HA-decorated liposome/mesoporous silica nanoplatform co-delivering BMF-219 and 5-FU enhances gastric cancer chemotherapy through Menin- and p53-associated apoptotic signaling.
Wang S, Li D, Zeng F, et al. · J Exp Clin Cancer Res 2026
- Clinical Integration of Menin Inhibitors in AML: Evolving Data and Therapeutic Perspectives.
Chen T, Kim G, Rahimi Y, et al. · Oncol Res 2026
- Menin-MLL inhibitors as a new therapeutic target for middle ear cholesteatoma.
Yamamoto-Fukuda T, Akiyama N, Kojima H · Sci Rep 2026
- The promise of menin inhibitors: from approval to triplet regimens.
Thakur RK, Wang ES · Hematology Am Soc Hematol Educ Program 2025
- Design, synthesis, and evaluation of Menin-targeting compounds for the treatment of acute Myelocytic leukemia (AML).
Mo J, Wang Y, Pan Y, et al. · Eur J Med Chem 2025
Also in development for Type 2 Diabetes Mellitus
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- ElecoglipronPhase 39 trials
AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
- ASC30 A1ASC30Phase 35 trials
Ascletis Pharma (China) Co., Limited · Chronic Weight Management, Obesity, Overweight
- SHR-3167Phase 35 trials
Jiangsu HengRui Medicine Co., Ltd. · Diabetes Mellitus, Type 2, Type 2 Diabetes, Type 2 Diabetes Mellitus
- HTD1801Berberine UrsodeoxycholatePhase 34 trials
Shenzhen HighTide Biopharmaceutical Ltd. · T2DM (Type 2 Diabetes Mellitus), Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
- DA-302168SPhase 33 trials
Chendu DIAO Pharmaceutical Group CO., LTD. · Overweight and Obesity, Type 2 Diabetes Mellitus
- TG103Phase 33 trials
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Type 2 Diabetes Mellitus, Overweight or Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.